CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
Cohen Fred E reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Fred E. Cohen received an equity grant of 9,795 shares of Common Stock in the form of restricted stock units. These RSUs vest 100% on the earlier of one year from the grant date or the day before the first Annual Meeting after the grant date, subject to his continuous service. Following this award, he holds 165,060 shares directly.
Gunasekaran Suresh reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Suresh Gunasekaran reported receiving an equity award of 9,795 shares of Common Stock, represented by restricted stock units (RSUs). These RSUs vest 100% on the earlier of one year after the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he holds 37,248 shares directly.
Bickerstaff George reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director George Bickerstaff received an equity award in the form of 9,795 shares of Common Stock represented by restricted stock units. These RSUs were granted at no cash cost to him and are part of his compensation.
The RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service through that time. Following this award, he holds 154,061 shares of Common Stock directly.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported receiving a grant of 9,795 restricted stock units (RSUs) of common stock at no cash cost, as a compensation award rather than an open‑market purchase.
The RSUs vest 100% on the earlier of the one‑year anniversary of the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he directly holds 195,737 shares of common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 21,998 shares of Common Stock on June 11, 2026 at a weighted average price of $24.0223 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 13, 2024, and left him with 649,642 shares held directly.
CareDx, Inc. reported results from its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders approved an amendment to the 2024 Equity Incentive Plan that increases the shares reserved under the plan by 1,600,000 shares, described as approximately 3.1% of common shares issued and outstanding. They also elected five directors to one-year terms, ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, approved on a non-binding advisory basis the compensation of named executive officers, and advised that say-on-pay votes be held every one year. A total of 48,142,732 shares, representing about 93% of outstanding shares entitled to vote, were present or represented by proxy, constituting a quorum.
John Hanna submitted a Form 144 reporting proposed dispositions of common stock. The filing lists 29,294 shares tied to an exercise of stock options with a 06/11/2026 action date, and 10,887 shares related to restricted stock units with a 04/15/2025 action date. The excerpt also shows recent 10b5-1 sales of 4,835 shares on 06/04/2026 and 10,282 shares on 04/16/2026 with dollar proceeds noted in the table.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 1,292 shares of common stock withheld by the company at $21.95 per share to cover tax obligations tied to the vesting of restricted stock units. After this tax-withholding disposition, he directly holds 112,632 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. sold 4,835 shares of Common Stock in an open-market transaction at a weighted average price between $24.00 and $24.02 per share on June 4, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024. Following the sale, he continues to hold 671,640 shares directly, indicating the transaction represents only a small portion of his overall position.